Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact
 May 15, 2012
 Clinical Applications of Vectra™ DA, a Multi-Biomarker Blood
 Test for Rheumatoid Arthritis Disease Activity
Speakers for this Event:
  • Alvin Wells, MD, PhD, Director, Rheumatology and Immunotherapy Center,
        Franklin, WI
       Learn More
  • David Chernoff, MD, Chief Medical Officer, Crescendo Bioscience®, Inc.,
        South San Francisco, CA
       Learn More
  • Clinical Applications of Vectra™ DA, a Multi-Biomarker Blood Test for Rheumatoid Arthritis Disease Activity

    Regular, precise assessments of RA disease activity, as recommended by EULAR and ACR, are important to improving patient outcomes1,2,3. Vectra DA – the first and only multi-biomarker blood test for RA – is an objective measure that reveals disease activity at the molecular level. Vectra DA simultaneously measures 12 key proteins consistently associated with RA disease activity, integrating them into a single, quantitative score to help inform patient management decisions.

    This presentation will include a brief background on the development & validation of Vectra DA delivered by Dr. David Chernoff, followed by a patient case study discussion led by Dr. Alvin Wells highlighting the application of Vectra DA in clinical practice.Register Today!

    Potential case scenarios discussed might include:

  • Assessing RA disease activity in patients with comorbidities
  • Resolving clinical discordances (between symptoms and labs or patient and
        physician assessments)
  • Quantifying RA disease activity during initiation of treatment to identify
        inadequate responders
  • Assessing risk of radiographic progression in patients in low disease activity
  • Tracking RA disease activity
  • Establishing a baseline assessment in newly diagnosed or referred patients
  • Facilitating a patient discussion regarding a change in management plan
  • Vectra DA is validated for use in adults diagnosed with RA. Test results are intended to aid in the assessment of disease activity in RA patients when used in conjunction with standard clinical assessment. This test is not intended or validated to diagnose RA.

    1Saag, Kenneth G, et al. American College of Rheumatology 2008 A&R (AC&R). 2008 June 15; 59(6): 762–784 2Smolen, Josef S, et al. ARD. 2010; 69: 631-637 3Bakker, M F, et al. ARD. 2007; 66(Suppl III): iii56–iii60


    Health Care Professionals involved in the treatment of rheumatoid arthritis

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com


    Alvin Wells, MD, PhD, Director, Rheumatology and Immunotherapy Center,
    Franklin, WI

    Dr. Wells is a board certified rheumatologist and the director of the Rheumatology and Immunotherapy Center in Franklin, WI. He is also an Adjunct Assistant Professor at Duke University Medical Center in Durham, NC. He received his MD from the University of South Florida College of Medicine in Tampa, FL. He earned his PhD in immunology from the University of South Carolina School of Medicine in Columbia, SC.

    Dr. Wells has over 20 years of research experience with an emphasis on inflammatory disorders. His clinical efforts focus on the management and treatment of all aspects of rheumatology with an emphasis on the use of ultrasound in clinical practice. An internationally renowned speaker, Dr. Wells has published numerous peer-reviewed journal articles, letters, book chapters, and abstracts. He is a member of Phi Beta Kappa, the American College of Rheumatology, and the American Institute of Ultrasound in Medicine.


    David Chernoff, MD, Chief Medical Officer, Crescendo Bioscience®, Inc.,
    South San Francisco, CA

    Dr. Chernoff has more than 20 years of experience in molecular diagnostics and is trained in Internal Medicine, Rheumatology/Immunology and Infectious Disease. He is the Chief Medical Officer for Crescendo Bioscience and is an Associate Professor of Medicine at the UCSF Medical Center.


    About Vectra™ DA
    Vectra DA is a quantitative, objective and reproducible multi-biomarker blood test that provides health care professionals with insight into the biology of rheumatoid arthritis. This test measures 12 key serum biomarkers and integrates them into an easy to interpret score to help inform patient management and complement clinical decisions. Vectra DA testing is performed at Crescendo Bioscience's state-of-the-art CLIA (clinical laboratory improvement amendments) facility and test results are reported back within 7-10 days of receipt of sample. Physicians can either receive test results via standard report forms or via the private web portal, VectraView. For more information on Vectra DA, please visit, http://www.vectra-da.com/.

    About Crescendo Bioscience®, Inc.
    Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience develops quantitative, objective, biology-based tests to provide rheumatologists with deeper clinical insights to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company’s website at http://www.crescendobio.com/.


    Register to request the recorded archive

    Sign Up to stay informed about future Vectra DA events and updates

    Copyright © 2016-2017 Honeycomb Worldwide Inc.